Lexpos News

Following representations made by Community Pharmacy England on behalf of community pharmacy owners, the Department of Health and Social Care (DHSC) has redetermined the April 2025 reimbursement prices for the following products, to reflect an increase in their NHS list prices. To avoid pharmacy owners dispensing these products at a loss, DHSC has agreed to grant [...]

The post Retrospective reimbursement prices for April 2025 appeared first on Community Pharmacy England.

NHS England previously announced the launch of a new community pharmacy Point of Care (PoC) IT Supplier Contractual Framework, which will allow pharmacy owners to choose which PoC system they use to make their clinical records for the Flu and COVID-19 vaccination services during the Autumn/Winter 2025/26 campaign. IT suppliers listed on the new framework will be assured by NHS [...]

The post IT supplier webinars ahead of launch vaccine IT system framework appeared first on Community Pharmacy England.

A new report from the All-Party Parliamentary Group (APPG) on Pharmacy calls for urgent reforms to medicines supply, after describing shortages as a “permanent and escalating feature” of the healthcare system. Published today, the report on an APPG inquiry into the issue concludes that shortages have become a constant and growing threat to NHS care [...]

The post MPs find medicines shortages now a systemic threat to NHS patient care appeared first on Community Pharmacy England.

MHRA Class 2 Medicines Recall: Zaditen 0.25 mg/ml, eye drops, solution (Laboratoires Théa) Drug alert number: EL(25)A/34 Date issued: 07 July 2025 Laboratoires Théa trading as Thea Pharmaceuticals Limited have notified the MHRA of an out of specification event related to environmental monitoring during manufacturing, which may increase the risk of microbial contamination of the [...]

The post Class 2 Medicines Recall: Zaditen 0.25 mg/ml, eye drops, solution (Laboratoires Théa) appeared first on Community Pharmacy England.

Pharmacy owners providing the Pharmacy Contraception Service are reminded that the Faculty of Sexual & Reproductive Healthcare (FSRH) advises that individuals use contraception whilst using Glucagon-like peptide-1 (GLP-1) agonists, with additional advice for those using tirzepatide. The statement from the FSRH can be found at: FSRH statement: Glucagon-like peptide-1 (GLP-1) agonists and oral contraception (Feb [...]

The post Reminder: GLP-1 receptor agonists interactions with oral contraception – safety guidance appeared first on Community Pharmacy England.